122 completed. 122 Phase 2, 8 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 122 | Completed 122 |
| Phase 1 | 8 | Completed 8 |
| Phase 3 | 7 | Completed 7 |
Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia SYH2053/placebo injection, Inclisiran (Leqvio®) 300mg - Hypercholesterolemia and Mixed Hyperlipidemia | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 156 | 2024-12-03 | 2026-02-19 |
| Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists RDX-002, Placebo - Triglycerides, Weight Gain Trajectory | Phase 2 | Completed | Response Pharmaceuticals | 68 | 2024-09-27 | 2026-07-02 |
| A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin - Hypercholesterolemia and Mixed Dyslipidemia | Phase 2 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 214 | 2023-06-02 | 2025-12-12 |
| Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD) HSK31679 low dose, HSK31679 medium dose, HSK31679 high dose - Hypercholesterolemia | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 210 | 2023-04-26 | 2024-04-09 |
| A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Bempedoic acid - Hypercholesterolemia | Phase 2 | Completed | Esperion Therapeutics, Inc. | 31 | 2023-01-12 | 2026-07-17 |
| A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Obicetrapib, Placebo - Dyslipidemia, Hypercholesterolemia | Phase 2 | Completed | NewAmsterdam Pharma | 102 | 2022-06-27 | 2024-10-29 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 381 | 2022-03-10 | 2024-12-09 |
| Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 119 | 2022-03-09 | 2024-07-03 |
| Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia Placebo, 250 mg OPP - Hyperlipidemias, Hypercholesterolemia | Phase 2 | Completed | Isa Naina Mohamed | 50 | 2021-10-18 | 2022-04-13 |
| Supplements, Placebo, or Rosuvastatin Study Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo - Hypercholesterolemia | Phase 2 | Completed | The Cleveland Clinic | 203 | 2021-04-23 | 2023-05-25 |
| A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia 180mg of ETC-1002(bempedoic acid), 120mg of ETC-1002(bempedoic acid), 60mg of ETC-1002(bempedoic acid) - Hypercholesterolemia | Phase 2 | Completed | Otsuka Pharmaceutical Co., Ltd. | 188 | 2021-03-24 | 2024-05-10 |
| Randomized Study of Obicetrapib in Combination With Ezetimibe Obicetrapib 5mg, Ezetimibe 10mg, Placebo - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 112 | 2021-02-23 | 2024-04-24 |
| Randomized Study of Obicetrapib as an Adjunct to Statin Therapy Obicetrapib - Dyslipidemias, High Cholesterol | Phase 2 | Completed | NewAmsterdam Pharma | 120 | 2021-02-18 | 2024-07-12 |
| Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C Inclisiran sodium, Placebo - Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia | Phase 2 | Completed | Novartis Pharmaceuticals | 312 | 2021-01-29 | 2024-06-20 |
| Effects of Atorvastatin in Graves' Orbitopathy (GO) Atorvastatin, Methylprednisolone - Thyroid Associated Ophthalmopathy, Hypercholesterolemia | Phase 2 | Completed | University of Pisa | 88 | 2020-06-01 | 2021-08-13 |
| A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia AK102, Placebos, Statins and/or Ezetimibe - Hypercholesterolemia | Phase 2 | Completed | Akeso | 262 | 2020-05-13 | 2023-03-02 |
| Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy CIVI 007 - Hypercholesterolemia | Phase 2 | Completed | Civi Biopharma, Inc. | 49 | 2019-11-11 | 2025-02-13 |
| A Long-term Study of AK102 in Patients With Hypercholesterolemia 450mg AK102, 300mg AK102, 150mg AK102 - Hypercholesterolemia | Phase 2 | Completed | Akeso | 796 | 2019-11-04 | 2023-03-02 |
| Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI Alirocumab, Sham Control - ST Elevation Myocardial Infarction, Acute Coronary Syndrome | Phase 2 | Completed | Population Health Research Institute | 97 | 2019-03-11 | 2022-04-11 |
| Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia IBI306, placebo - Hypercholesterolemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 60 | 2019-03-07 | 2023-11-18 |
Showing 20 of 122. Sign in to see all of them.
Dyslipidemias (21) · Hyperlipidemias (16) · Cardiovascular Diseases (10) · Hyperlipoproteinemia Type II (7) · Hypertriglyceridemia (7) · Atherosclerosis (6) · Hypertension (6) · Lipid Metabolism Disorders (6) · Metabolic Diseases (5) · Metabolic Syndrome (5) · Coronary Disease (3) · Homozygous Familial Hypercholesterolemia (3) · Hypercholesterolemia, Autosomal Dominant, 3 (3) · Obesity (3)
Nutritional and Metabolic Diseases (121) · Metabolic Diseases (117) · Lipid Metabolism Disorders (116) · Hyperlipidemias (106) · Dyslipidemias (101) · Vascular Diseases (14) · Cardiovascular Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Arterial Occlusive Diseases (7) · Arteriosclerosis (7) · Genetic Diseases, Inborn (7) · Glucose Metabolism Disorders (7) · Pathological Conditions, Signs and Symptoms (7) · Endocrine System Diseases (6) · Hyperlipoproteinemias (6)
Atorvastatin (20) · Ezetimibe (13) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (9) · alirocumab (8) · evolocumab (8) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (6) · gemcabene (5) · mipomersen (5) · Pravastatin (4) · Rosuvastatin Calcium (4) · bococizumab (4) · 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (3) · BMS201038 (3) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (2) · Fenofibrate (2)
Esperion Therapeutics, Inc. (9) · Amgen (7) · Kastle Therapeutics, LLC (5) · NeuroBo Pharmaceuticals Inc. (5) · Sanofi (5) · Micropharma Limited (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · NewAmsterdam Pharma (4) · Pfizer (4) · Regeneron Pharmaceuticals (4) · Aegerion Pharmaceuticals, Inc. (3) · Eli Lilly and Company (3) · Karo Bio AB (3) · Merck Sharp & Dohme LLC (3) · National Center for Complementary and Integrative Health (NCCIH) (3)
United States (61) · Canada (28) · Netherlands (12) · Japan (11) · Australia (9) · Czechia (8) · Denmark (8) · Spain (8) · China (7) · France (7) · Sweden (7) · Germany (6) · United Kingdom (6) · Belgium (5) · Italy (5)
Ron Haberman, MD (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Alison L Gibbs, PhD (1) · Arshed A Quyyumi, MD (1) · Barry Lubin, MD (1) · Brad West, ND (1) · Charles L Shear, DrPH (1)
PMID 30183102, PMID 37994400, PMID 26872608, PMID 20707601, PMID 21518985, PMID 24014831, PMID 25060413, PMID 28181260, PMID 29037448, PMID 16996859, PMID 17030154, PMID 17298834, PMID 17325296, PMID 17384435, PMID 17392721, PMID 17434849, PMID 17556685, PMID 17987126, PMID 19364997, PMID 19500003, PMID 19506174, PMID 19810001, PMID 19843338, PMID 20008831, PMID 20220185, PMID 20378080, PMID 20428452, PMID 20527967, PMID 20660224, PMID 20668250, PMID 20875216, PMID 21593041, PMID 22089718, PMID 22118569, PMID 22264573, PMID 22301925, PMID 22463922, PMID 22484031, PMID 22507979, PMID 22561556, PMID 22633824, PMID 22698766, PMID 23113833, PMID 23148122, PMID 23174266, PMID 23221573, PMID 23262496, PMID 23840361, PMID 23884353, PMID 24074303
2005 (1), 2015 (1), 2017 (1), R01HL042554 (1), R01HL070742 (1), U01HL044315 (1)